Fruitful decade of fungal metabolites as anti-diabetic agents from 2010 to 2019: emphasis on α-glucosidase inhibitors

Abstract

AbstractIn recent years the prevalence of diabetes has increased globally and by 2040 the number of diabetic people has been estimated to increase to 642 million. Various classes of drugs are available to treat Type ll diabetes. However, these drugs are associated with certain side effects. α-Glucosidase is an intriquing target enzyme to treat Type II diabetes, and α-glucosidase inhibitors are considered as first-line drugs for Type ll patients. Fungi, in general, produce natural products with some amazing chemical diversity and many fungal metabolites have illustrated a wide range of biological and pharmacological effects. In this review the focus is on describing the α-glucosidase effects and their potential as anti-diabetic agents of various metabolites isolated from fungi.